Loading…
Reported covered position: Director, Office of Intergovernmental and External Affairs, U.S. Dept. of Health and Human Services (2009-2015); Chief of Staff, Office of Congressional and Intergovernmental Affairs, U.S. Dept. of Labor (1999-2001)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
LYKOS THERAPEUTICS via FORBES-TATE
2024 · second_quarter · 2A
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Source: Senate LDA
| A PLACE FOR MOM, INC. |
| 4 |
| 2021–2022 |
| HEALTHY.IO (US), INC. | 4 | 2023–2024 |
| INDEPENDENT PHARMACY COOPERATIVE | 4 | 2023–2024 |
| SPERO THERAPEUTICS, INC. | 4 | 2021–2022 |
| VENATORX PHARMACEUTICALS | 4 | 2021–2022 |
| CLARITEV (FKA MULTIPLAN CORPORATION) | 3 | 2024 |
| CONDUENT BUSINESS SERVICES, LLC | 3 | 2023–2024 |
| CYTOVALE INC | 3 | 2024 |
| PROCISEDX CORPORATION | 3 | 2023 |
| STORER TEST EXPRESS DBA BUSTEST EXPRESS | 2 | 2021–2022 |
| VERDE TECHNOLOGIES | 2 | 2021–2022 |
| ALIVECOR, INC. | 1 | 2022 |
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2024.
Transportation issues regarding medical transport; Issues related to S. 1939 - FAA Reauthorization Act of 2024.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Lower Costs, More Transparency Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Transparency Act of 2023
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Pharmacy Benefit Manager Reform Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2023.
Transportation issues regarding medical transport; Issues related to S.1939 - FAA Reauthorization Act of 2023.
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2023.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Modernizing and Ensuring PBM Accountability Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client: A PLACE FOR MOM, INC. · Firm: FORBES-TATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2024 · second_quarter · 2A
Issues pertaining to payment for healthcare services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2024 · second_quarter · Q2
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2024 · second_quarter · Q2
Transportation issues regarding medical transport; Issues related to S. 1939 - FAA Reauthorization Act of 2024.
Issues related to Medicare reimbursement, workforce issues, and the implementation of the No Surprises Act (PL 116-260).
Issues related to Medicare reimbursement, workforce issues, and the implementation of the No Surprises Act (PL 116-260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CYTOVALE, INC. via FORBES-TATE
2024 · second_quarter · Q2
Issues related to infectious disease diagnosis.
Issues related to infectious disease diagnosis and value based care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2024 · second_quarter · Q2
Issues pertaining to payment for healthcare services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2024 · second_quarter · Q2
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2024 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2024 · second_quarter · Q2
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LYKOS THERAPEUTICS via FORBES-TATE
2024 · second_quarter · Q2
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
HEALTHY.IO (US), INC. via FORBES-TATE
2024 · second_quarter · Q2
Issues related to kidney health and Medicare Advantage.
Issues related to kidney health and Medicare Advantage.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2024 · second_quarter · RR
Issues pertaining to payment for healthcare services.
CYTOVALE, INC. via FORBES-TATE
2024 · first_quarter · Q1
Issues related to infectious disease diagnosis and value-based care.
Issues related to infectious disease diagnosis.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2024 · first_quarter · Q1
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2024 · first_quarter · Q1
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LYKOS THERAPEUTICS via FORBES-TATE
2024 · first_quarter · Q1
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2024 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2024 · first_quarter · Q1
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
HEALTHY.IO (US), INC. via FORBES-TATE
2024 · first_quarter · Q1
Issues related to kidney health and Medicare Advantage.
Issues related to kidney health and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2024 · first_quarter · Q1
Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260).
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2024.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CONDUENT BUSINESS SERVICES, LLC via FORBES-TATE
2024 · first_quarter · Q1
Issues related to Medicaid enrollment broker issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CYTOVALE, INC. via FORBES-TATE
2024 · first_quarter · RR
Issues related to infectious disease diagnosis.
HEALTHY.IO (US), INC. via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to kidney health and Medicare Advantage.
Issues related to kidney health and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260).
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
CONDUENT BUSINESS SERVICES, LLC via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to Medicaid enrollment broker issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · fourth_quarter · Q4
Healthcare initiatives related to novel antibody technology platform.
Issues related to pandemic preparedness.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LYKOS THERAPEUTICS via FORBES-TATE
2023 · fourth_quarter · Q4
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · fourth_quarter · 4T
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHY.IO (US), INC. via FORBES-TATE
2023 · fourth_quarter · RR
Issues related to kidney health and Medicare Advantage.
Issues related to kidney health and Medicare Advantage.
CONDUENT BUSINESS SERVICES, LLC via FORBES-TATE
2023 · fourth_quarter · RR
Issues related to Medicaid enrollment broker issues.
MOLINA HEALTHCARE, INC. via FORBES-TATE
2023 · third_quarter · Q3
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LYKOS THERAPEUTICS via FORBES-TATE
2023 · third_quarter · Q3
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2023 · third_quarter · Q3
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · third_quarter · Q3
Healthcare initiatives related to novel antibody technology platform.
Issues related to pandemic preparedness.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · third_quarter · Q3
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2023 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2023 · third_quarter · Q3
Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260).
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2023.
Issues related to Medicare reimbursement, workforce issues and implementation of the No Surprises Act (PL 116-260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
PROCISEDX CORPORATION via FORBES-TATE
2023 · second_quarter · 2T
Issues related to point-of-care systems for value-based care and specialty drug delivery.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2023 · second_quarter · Q2
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Transportation issues regarding medical transport; Issues related to S.1939 - FAA Reauthorization Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · second_quarter · Q2
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Issues related to pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · second_quarter · Q2
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2023 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2023 · second_quarter · Q2
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LYKOS THERAPEUTICS via FORBES-TATE
2023 · second_quarter · Q2
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
PROCISEDX CORPORATION via FORBES-TATE
2023 · first_quarter · Q1
Issues related to point-of-care systems for value-based care and specialty drug delivery.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LYKOS THERAPEUTICS via FORBES-TATE
2023 · first_quarter · Q1
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
MOLINA HEALTHCARE, INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2023 · first_quarter · Q1
Issues related to pandemic preparedness.
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform; Issues related pandemic preparedness.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2023 · first_quarter · Q1
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2023 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2023 · first_quarter · Q1
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Transportation issues regarding medical transport.
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
LYKOS THERAPEUTICS via FORBES-TATE
2023 · first_quarter · RR
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
PROCISEDX CORPORATION via FORBES-TATE
2023 · first_quarter · RR
Issues related to point-of-care systems for value-based care and specialty drug delivery.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · fourth_quarter · 4A
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · fourth_quarter · Q4
Healthcare initiatives related to novel antibody technology platform.
Issues related to COVID funding.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2022 · fourth_quarter · Q4
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Workforce shortage issues in the medical transport and healthcare field.
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
VENATORX PHARMACEUTICALS via FORBES-TATE
2022 · third_quarter · 3T
Issues related to biopharmaceutical policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2022 · third_quarter · Q3
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Transportation issues regarding medical transport.
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
A PLACE FOR MOM, INC. via FORBES-TATE
2022 · third_quarter · 3T
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
MOLINA HEALTHCARE, INC. via FORBES-TATE
2022 · third_quarter · Q3
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2022 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · third_quarter · Q3
Issues related to COVID funding.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · third_quarter · Q3
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALIVECOR, INC. via FORBES-TATE
2022 · third_quarter · RR
Issues related to ITC.
Issues related to ITC.
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · second_quarter · Q2
Issues related to COVID funding.
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VENATORX PHARMACEUTICALS via FORBES-TATE
2022 · second_quarter · Q2
Issues related to biopharmaceutical policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · second_quarter · Q2
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2022 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SPERO THERAPEUTICS, INC. via FORBES-TATE
2022 · second_quarter · 2T
Issues related to biopharmaceutical research, development and commercialization.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2022 · second_quarter · Q2
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2022 · second_quarter · Q2
Transportation issues regarding medical transport.
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Workforce shortage issues in the medical transport and healthcare field.
A PLACE FOR MOM, INC. via FORBES-TATE
2022 · second_quarter · Q2
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2022 · first_quarter · Q1
Healthcare initiatives related to novel antibody technology platform; Issues related to COVID funding; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2022 · first_quarter · 1T
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
VENATORX PHARMACEUTICALS via FORBES-TATE
2022 · first_quarter · Q1
Issues related to biopharmaceutical policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2022 · first_quarter · Q1
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2022 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STORER TEST EXPRESS DBA BUSTEST EXPRESS via FORBES-TATE
2022 · first_quarter · Q1
Issues related to Appropriations, COVID Relief Funds, HRSA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPERO THERAPEUTICS, INC. via FORBES-TATE
2022 · first_quarter · Q1
Issues related to biopharmaceutical research, development and commercialization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2022 · first_quarter · Q1
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2022 · first_quarter · Q1
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
A PLACE FOR MOM, INC. via FORBES-TATE
2022 · first_quarter · Q1
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2022 · first_quarter · RR
Issues related to Medicare payment and extenders.
Issues related to Medicare payment and extenders.
Issues related to Medicare payment and extenders.
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2021 · fourth_quarter · Q4
Healthcare initiatives related to novel antibody technology platform.
Healthcare initiatives related to novel antibody technology platform.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERDE TECHNOLOGIES via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
VENATORX PHARMACEUTICALS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to biopharmaceutical policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to rare disease, drug development, reimbursement, and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STORER TEST EXPRESS DBA BUSTEST EXPRESS via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to Appropriations, COVID Relief Funds, HRSA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPERO THERAPEUTICS, INC. via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to biopharmaceutical research, development and commercialization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOLINA HEALTHCARE, INC. via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to Medicaid and COVID-19.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
A PLACE FOR MOM, INC. via FORBES-TATE
2021 · fourth_quarter · Q4
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
SPERO THERAPEUTICS, INC. via FORBES-TATE
2021 · fourth_quarter · RR
Issues related to biopharmaceutical research, development and commercialization.
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Workforce shortage issues in the medical transport and healthcare field.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Issues related to alternative treatments for PTSD and research in treating behavioral health challenges.
Transportation issues regarding medical transport.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Workforce shortage issues in the medical transport and healthcare field.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare reimbursement, workforce issues and implementation of H.R.3630 - No Surprises Act (Public Law 116-260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare payment and extenders.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and other Infrastructure Packages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE